In breast and colorectal cancer models, pharmacological inhibition of CHD1L results in the entrapment of CHD1L on chromatin, deprotection of nuclear PAR chains, and robust induction of PARthanatos, as measured by AIF translocation to the nucleus [76]. This evidence concerns the gene CHD1L and colorectal cancer.